A new approach pioneered at the University of Pennsylvania's Abramson Cancer Center may provide a new path towards treating Acute Myeloid Leukaemia (AML) with CAR T cells.

To treat AML, investigators have to target a specific protein - CD33 - that's also expressed on healthy cells, meaning the therapy cannot attack the cancer without causing other serious damage to the residual normal bone marrow.

The new method uses the gene editing tool CRISPR/Cas9 to remove CD33 from healthy blood-forming stem cells, leaving the cancerous cells as the only targets left for the CD33 hunter cells to attack.

Penn researchers and their collaborators at the National Institutes of Health published their proof-of-concept findings in Cell.

AML is the second most common type of leukaemia, and the American Cancer Society estimates there will be almost 20,000 new cases in the United States this year.

Many of these patients will undergo a bone marrow transplant.

To treat a related leukaemia called acute lymphoid leukaemia (ALL), investigators at Penn previously developed CAR T cell therapy, which involves collecting patients' own immune T cells, reprogramming them to kill cancer, and then infusing them back into patients' bodies.

Currently, both CAR T cell therapies approved for use by the U.S. Food and Drug Administration target cells that express a protein called CD19, for ALL and non-Hodgkin's lymphoma.

However, this is not an effective target for AML, since AML does not express CD19.

Researchers have therefore been looking for other potential cellular targets.

One promising example is a protein known as CD33, but previous attempts to target CD33 have proven damaging to healthy cells.

While damage to healthy cells could be prevented by making the CART cells short-lasting, this would defeat the purpose of one of CAR T's greatest strengths - their ability to last for years, circulate in the body, and protect the patient from relapse.

"This therapy is meant to be a true living drug, and we know that CAR T cells can live on in patients' bodies for years after infusion, so turning them off would be self-defeating," said the study's co-senior author Saar I. Gill, MD, PhD, an assistant professor of Hematology-Oncology at Penn.

Cynthia E. Dunbar, MD, a senior investigator at the National Heart, Lung, and Blood Institute, is a co-senior author. The co-first authors are Miriam Yunhee Kim, MD, then a post-doctoral researcher in Gill's lab, and Kyung-Rok Yu PhD, a post-doctoral fellow under Dunbar.

"This study represents a significant advance toward effective and safe targeting of leukaemia cells using CAR T cells," Dunbar said. "A key to this advance is the use of next-generation gene-editing technology to achieve this type of antigen-specific immunotherapy, even when the target is also present on normal bone marrow cells."

Since the hunter cells are unable to distinguish between normal and malignant cells, the researchers developed an innovative approach to genetically engineer the normal stem cells so they no longer resemble the leukaemia.

They used the CRISPR/Cas9 gene editing tool to remove CD33 from healthy cells.

To their surprise, healthy stem cells lacking CD33 functioned normally.

This resulted in the CD33 protein now being unique to the leukaemia cells, leaving the CAR T cells free to attack.

"None of the existing CAR T approaches target a cancer-specific antigen - other than EGFRvIII in brain cancer - but with this approach, we can create a cancer-specific antigen, which allows us to unleash CAR T cells to their maximal capacity," Gill said.

Gill and his team have already put this concept into practice and have shown it to be effective in mouse and monkey models.

They've also demonstrated its effect on human cells in a laboratory setting.

"Think of this as bone marrow transplant 2.0; the next generation of transplants," Gill said. "It gives you a super powerful anti-leukaemia effect thanks to the CAR T cells, but at the same time it has the potential to get rid of the main toxicity."

Their next step is to move this approach into human trials at Penn.

Source: Perelman School of Medicine - University of Pennsylvania